Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, Fixed-sequence, Open-label Study to Assess the Effects of Savolitinib on the Pharmacokinetics of Substrates of Human Transporters Digoxin (P-gp), Rosuvastatin (OATP1B1/3), Metformin (OCT2, MATE1/2K), and Furosemide (OAT1/3) in Healthy Male Subjects

NCT05768360 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT05768360
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05768360 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, Fixed-sequence, Open-label Study to Assess the Effects of Savolitinib on the Pharmacokinetics of Substrates of Human Transporters Digoxin (P-gp), Rosuvastatin (OATP1B1/3), Metformin (OCT2, MATE1/2K), and Furosemide (OAT1/3) in Healthy Male Subjects
Lead sponsor
AstraZeneca
Phase
Phase 1
Overall status
Completed
Start date
April 25, 2023
Completion date
June 24, 2023
Enrollment
6 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

healthy male subjects